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Background: Ebola viruses (EBOVs) cause severe hemorrhagic fever with a high mortality rate. At present, there are
no licensed vaccines or efficient therapies to combat EBOV infection. Previous studies have shown that both
humoral and cellular immune responses are crucial for controlling Ebola infection. CD8+ T cells play an important
role in mediating vaccine-induced protective immunity. The objective of this study was to identify H-2d-specific T
cell epitopes in EBOV glycoproteins (GPs).
Results: Computer-assisted algorithms were used to predict H-2d-specific T cell epitopes in two species of EBOV
(Sudan and Zaire) GP. The predicted peptides were synthesized and identified in BALB/c mice immunized with
replication-deficient adenovirus vectors expressing the EBOV GP. Enzyme-linked immunospot assays and
intracellular cytokine staining showed that the peptides RPHTPQFLF (Sudan EBOV), GPCAGDFAF and LYDRLASTV
(Zaire EBOV) could stimulate splenoctyes in immunized mice to produce large amounts of interferon-gamma.
Conclusion: Three peptides within the GPs of two EBOV strains were identified as T cell epitopes. The identification
of these epitopes should facilitate the evaluation of vaccines based on the Ebola virus glycoprotein in a BALB/c
mouse model.
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Ebola viruses (EBOVs) are enveloped, non-segmented,
negative-strand RNA viruses belonging to the family
Filoviridae. They are known to cause lethal hemorrhagic
fever in humans and non-human primates with a mor-
tality rate up to 90% [1,2]. EBOVs transmit among
human and nonhuman primate populations through
contact with infected blood, bodily fluids or tissues;
moreover, the intentional release of EBOVs would prob-
ably result in mucosal infection by small-particle aerosol
dispersion [3-5]. Although a considerable worldwide
threat exists should EBOVs spread globally, currently,
there are no licensed vaccines or effective treatments.
Five different species of EBOV have been identified:
Zaire (ZEBOV); Sudan (SEBOV); Ivory Coast; Reston;
and the newly discovered Bundibugyo [6]. Among these
species, infections with SEBOV and ZEBOV are the most
commonly occurring and have caused the greatest* Correspondence: houlihua@sina.com; chenwei0226@yahoo.com.cn
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reproduction in any medium, provided the ornumber of deaths. The EBOV envelope glycoprotein
(EBOV-GP) forms spikes on the surface of mature vir-
ions, and has been shown to be an effective target for
vaccine design [7]. Several vaccine candidates based on
the EBOV-GP have been shown to protect non-human
primates: Ebola virus-like particles [8,9]; a replication-
deficient adenovirus expressing the EBOV-GP [10-13]; a
replication-competent vesicular stomatitis virus expres-
sing EBOV-GP [14-16]; and a recombinant paramyxo-
virus expressing EBOV-GP [17]. Although humoral
responses to EBOV are very important, EBOV-specific
CD8+ cytotoxic T lymphocytes (CTLs) are necessary for
viral control and clearance (reviewed in [18]).
CTL epitopes are increasingly important as research
targets for the development of vaccines and immuno-
therapies, and are also very useful for evaluating the effi-
cacy of vaccines. Experimental methods for identifying
CTL epitopes involve multiple overlapping peptides
spanning individual antigens, as well as complete viral
proteomes. These methods are expensive and time-
consuming. Computational prediction methods
minimize the number of validation experiments, and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[19]. There are many epitope prediction programs now
available on the internet, and computational prediction
of CTL epitopes has become a topic of vigorous research
and development activity.
For EBOVs, mouse model represents the necessary
first step in the development of a potential vaccine
candidate that can then be further tested in primates
and humans [20,21]. Identification of CD8+ T cell epi-
topes in EBOV antigens presented by murine major his-
tocompatability complex (MHC) molecules is essential
to prove the effectiveness of any vaccination strategy in
this animal model. In this study, the H-2d-specific T cell
epitopes in the envelope glycoprotein (GP) of SEBOV
and ZEBOV were predicted using software. The pre-
dicted peptides were synthesized and identified by intra-
cellular cytokine assays using splenocytes from rAd-
EBOV-GP (replication-deficient adenovirus vectors
expressing the EBOV GP)-vaccinated mice.
Results
Computational prediction of EBOV-GP CTL epitopes
The prediction of class I MHC-restricted epitopes of
SEBOV-GP and ZEBOV-GP sequences for the K, D, and L
loci of the mouse haplotype H-2d (BALB/c) was per-
formed using prediction programs available on the inter-
net (Table 1). For each program, the peptides that ranked
among the top five prediction results were selected. All
selected peptides were rearranged according to frequency
of occurrence in the top five ranking for all the prediction
programs. Twelve peptides were selected for further eva-
luation (Table 2). Among those peptides, LYDRLASTV
(LV, H-2Kd) and EYLFEVDNL (EL, H-2Kd) were previ-
ously reported as CTL epitopes in ZEBOV-GP [21].
Identification of H-2d-restricted CD8+ T cell epitopes in
SEBOV-GP
The rAd-EBOV-GP was observed to induce a robust














EpitopePrediction.htmEbola virus challenge [12]. To identify H-2d specific CD8+
T cell epitopes in SEBOV-GP, a double injection of a re-
combinant replication-deficient adenovirus serotype 5
expressing the glycoprotein of SEBOV (Ad5-GPS) was
performed to obtain a strong cellular immune response.
Splenocytes were harvested 10 days after the second
immunization and re-stimulated in vitro with the pre-
dicted peptides in an interferon (IFN)-γ enzyme-linked
immunospot (ELISPOT) assay (Figure 1A, B). Of the six
predicted peptides, only RPHTPQFLF (RF) showed
specific stimulation of an IFN-γ response. LV, which was
identified as the H-2d-specific epitope in ZEBOV-GP
[22], showed no response.
To further confirm RF was a specific CTL CD8+ epi-
tope, BALB/c mice were immunized with Ad5-GPS or
control (Ad5-EGFP) twice with an interval of 4 weeks.
At 10 days after the second immunization, splenocytes
were re-stimulated in vitro with RF or without peptides,
in the presence of brefeldin A for 6 h. This was followed
by intracellular IFN-γ staining and flow cytometry ana-
lysis (Figure 1C, D). It was shown that RF could stimu-
late splenocytes from mice immunized with Ad5-GPS,
resulting in a robust IFN-γ response in CD8+ T cells.
The splenocytes from mice immunized with control, or
cells without stimulation, demonstrated no response. RF
represents the first H-2d-restricted peptide described in
SEBOV-GP.Identification of H-2d-restricted CD8+ T cell epitopes in
ZEBOV-GP
Using the same strategy, two H-2d-restricted epitopes
were identified in ZEBOV-GP (Figure 2). BALB/c mice
were immunized twice with a recombinant replication-
deficient adenovirus serotype 5 expressing the glycopro-
tein of ZEBOV (Ad5-GPZ), splenocytes were re-
stimulated with the predicted peptides, and positive
IFN-γ T cell responses were noted with LV and
GPCAGDFAF (GF) (Figure 2A, B). LV, a CTL epitope of
ZEBOV-GP specific to H-2Kd had been identified previ-
ously [22]. However, GF represented a novel epitope in
ZEBOV-GP. EL, which was identified as a H-2Kd-specific
epitope in ZEBOV-GP [22] did not result in an IFN-γ res-
ponse from T cells in this study. Further intracellularTable 2 Amino acid sequence of the predicted SEBOV-GP
and ZEBOV-GP CD8+ T cell epitopes
Ebola virus peptides
Subtypes H-2Kd H-2Dd H-2Ld
Zaire Ebola
virus
LYDRLASTV (LV) QGPTQQLKT (QT) GPCAGDFAF (GF)
EYLFEVDNL (EL) KKPDGSECL (KL) LPQAKKDFF (LF)
Sudan Ebola
virus
LYDRLASTV (LV) TGPCDGDYA (TA) RPHTPQFLF (RF)
SFFVWVIIL (SL-9) KKPDGSECL (KL) SYYATSYL (SL-8)
Figure 1 Identification of H-2d-restricted epitopes in SEBOV-GP. (A, B) BALB/c mice were immunized with Ad5-GPS twice, at an interval of
4 weeks. Splenocytes were harvested 10 days after the second immunization and re-stimulated in vitro with the predicted peptides from SEBOV-
GP for use in IFN-γ ELISPOT assays. RF was observed to induce strong IFN-γ-specific spot forming. A negative control without peptide was
included. (C, D) To further confirm the peptide identified in the ELISPOT assay, BALB/c mice were immunized with Ad5-GPS or Ad5-EGFP (as a
control) twice, splenocytes were re-stimulated in vitro with RF or without peptides and the responding CD8+ T cells were visualized by
intracellular IFN-γ staining.
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GPZ was sufficient to stimulate a strong CD8+ T cell
response against GF, whereas control Ad5-EGFP did not
(Figure 2C). At the same time, GF was more efficient at
inducing IFN-γ secretion than LV (Figure 2D), suggesting
that GF represented a more sensitive epitope for the de-
tection of IFN-γ, especially when the level of IFN-γ
secretion was low.
Discussion
In this study, we identified H-2d-restricted CD8+ T cell
epitopes in SEBOV-GP and ZEBOV-GP. The CD8+ T
cell epitopes in SEBOV-GP and ZEBOV-GP were pre-
dicted using internet-based prediction programs. The
peptides with the highest scores and greatest frequencyin the top five rankings for all programs were selected,
with two peptides for each loci (D, K and L) of the
mouse haplotype H-2d identified.
Three peptides, RF (H-2Ld) in SEBOV-GP, along with
LV (H-2Kd) and GF (H-2Ld) in ZEBOV-GP, out of 12
predicted peptides were able to induce strong IFN-γ
responses. RF and GF are newly identified epitopes in
SEBOV-GP and ZEBOV-GP, respectively. LV appeared
in the predicted CTL epitopes for both SEBOV-GP and
ZEBOV-GP, and was previously identified as an effective
epitope in ZEBOV-GP [22]. However LV could not
induce IFN-γ secretion from the splenocytes of Ad5-
GPS-immunized mice in this study. The amino acid
homology between SEBOV-GP and ZEBOV-GP was
70.1%, and we are uncertain as to why there were
Figure 2 Identification of H-2d-restricted epitopes in ZEBOV-GP. (A, B) BALB/c mice were immunized with Ad5-GPZ twice, at an interval of
4 weeks. Splenocytes were harvested 10 days after the second immunization and re-stimulated in vitro with the predicted peptides from ZEBOV-
GP for use in the IFN-γ ELISPOT assay. GF and LV were observed to induce IFN-γ-specific spot forming. A negative control without peptide was
included. (C, D) To further confirm the peptides identified in the ELISPOT assay and to compare the stimulation effect of GF, LV and EL, BALB/c
mice were immunized with Ad5-GPZ or Ad5-EGFP (as a control) twice. Splenocytes were re-stimulated in vitro with GF, LV, EL or without peptides
and the responding CD8+ T cells were visualized by intracellular IFN-γ staining.
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previously reported as a CTL epitope in ZEBOV-GP
[22], was not effective in our study, a result similar to
that seen in a previous study using DNA as the vacci-
nation platform [23].
Intracellular cytokine staining and ELISPOT assays are
the most commonly used quantitative assays for count-
ing peptide-specific T cells. ELISPOT is a key method-
ology used in the identification of novel epitopes
because of its high throughput. However, intracellular
cytokine staining has the added advantage that qualita-
tive analysis can be performed, making it possible to
identify specific cell subpopulations that contribute to
cytokine production. Wells that were positive for the
primary ELISPOT assay can be retested by intracellular
cytokine staining to determine if cytokine-secreting cellsare CD4+ or CD8+. The intracellular cytokine staining
results showed that RF and GF are EBOV-GP specific
and induced robust IFN-γ responses in CD8+ T cells,
demonstrating that they are the novel CTL epitopes.
Interestingly, the two novel CTL epitopes were H-2Ld
restricted. Intracellular IFN-γ staining in splenocytes of
Ad5-GPZ-immunized mice showed that GF was able to
induce stronger development of a peptide-specific IFN-γ
response in CD8+ T cells, suggesting that GF represents
a more efficient CD8+ CTL epitope in ZEBOV-GP.
In silico methods together with in vivo/in vitro valid-
ation have proven to be a quick and effective strategy for
identifying T cell epitopes [24-26]. Compared with the
expensive and time-consuming overlapping peptides
method, this strategy not only reduces the workload and
cost, but also improves the rate of test, and has become
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To predict a novel epitope, programs based on proteaso-
mal cleavage, TAP transport, MHC binding or a combin-
ation of these have been developed. However, compared
with highly selective peptide binding to MHC molecules,
proteasomal cleavage and TAP transport have little in-
fluence on epitope generation [27]. There is significant
interest in the development of computational methods
for predicting the binding capability of peptides to MHC
molecules as a first step towards selecting peptides for
actual screening. In this study, MHC binding-based algo-
rithms, integrated methods, as well as structure-based
algorithms were used. To compare the predictive accur-
acy of the programs in this study, the ranking of the
identified peptides in each program were summarized
(Table 3). NetMHC, a prediction program based on arti-
ficial neural networks (ANNs) and position-specific scor-
ing matrices (PSSMs), seemed to provide the best
performance. This result corresponded with previous
comparison tests [28,29]. Other prediction programs,
such as IEDB (SMM), NetCTLpan, SYFPEITHI, BIMAS,
nHLAPred (Compred) and Propred-1 also demonstrated
high predictive accuracy. IEDB (SMM) is one of the class
I MHC peptide-binding prediction methods provided
through the immune epitope database analysis resource
that models binding specificity of an MHC molecule
using PSSMs [27]. NetCTLpan is a pan-specific MHC
class I epitope predictor, which integrates prediction of
proteasomal cleavage, TAP transport efficiency and
peptide-MHC binding [30]. SYFPEITHI, one of the first
algorithms available online, is a motif-matrix-based pre-
diction method for MHC binding prediction [31]. How-
ever, PREDEP, a structure-based algorithm, showed the
lowest performance levels in our study. It would appear
that sequence-based methods are computationally more
efficient than structure-based methods. However,
sequence-based methods do not provide a structural in-
terpretation of results, which is of importance for









BIMAS 5 2 2
IEDB (SMM) 2 1 1
NetCTLpan 2 3 1
NetMHC 1 1 1
nHLAPred (Compred) 5 3 7
PREDEP - 93 4
Propred-1 5 2 2
SYFPEITHI 1 1 4To date, some EBOV derived CD8+ T cell epitopes
have been identified. Rao et al. identified a H-2k-specific
and two H-2d-specific murine EBOV-GP CTL epitope
by immunizing mice with a liposome encapsulated by
irradiated EBOV [22,32]. However, one of the identified
CTL epitopes (EL) showed no response in another study
[23], and also in this work. Other studies have used
Venezuelan equine encephalitis virus-based EBOV vac-
cines to identify the H-2d- or H-2b-restricted CTL epi-
topes in EBOV GP, NP, VP24, VP30, VP35 and VP40
[33,34]. At the same time, Simmons et al. attempted to
map murine CTL epitopes of EBOV-NP using overlap-
ping peptides. They identified a single H-2d- and two H-
2b-restricted CTL epitopes [35]. Following on from this,
a combination of computational prediction together with
in vitro/in vivo validation methods were used to identify
the HLA-A2.1-specific CTL epitopes in EBOV-NP [36].
However, those predictions are almost entirely based
upon ZEBOV, and no effective SEBOV-GP CTL epitope
has been reported. Here, we identified a H-2d-restricted
CTL epitope in SEBOV-GP, and at the same time, a
novel H-2d-specific epitope in ZEBOV-GP.
Conclusions
RF and GF were the best candidates to measure CD8+ T
cell responses in BALB/c mice model after vaccination
with SEBOV or ZEBOV vaccines based on EBOV-GP.
The identification of H-2d-restricted CD8+ T cell epi-
topes for EBOV-GP will contribute to analyzing the effi-
cacy of different vaccination protocols based upon the
GP in the BALB/c mice model. Our findings also illus-
trate how a hybrid immune-computational approach
may be useful for biologists in identifying candidate
epitopes.
Methods
Computational prediction of candidate CTL epitopes in
EBOV-GP
H-2d (H-2Kd, H-2Dd and H-2Ld)-restricted epitopes of
SEBOV-GP and ZEBOV-GP were predicted using
BIMAS, IEDB (SMM), NetMHC, NetCTLpan,
nHLAPred (Compred), PREDEP, ProPred-I and SYF-
PEITHI (Table 1). The top five ranking peptides from
each program were selected, and rearranged by fre-
quency of occurrence in all prediction programs. Con-
sidering the scores of peptides in the prediction program
and their frequency of ranking in the top five, the most
likely H-2Kd-, H-2Dd- or H-2Ld-specific binding pep-
tides (two peptides for each) were selected for further
evaluation.
Peptides
All peptides for identification were synthesized by GL
Biochem Ltd (Shanghai, China) and provided at >95%
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tography and mass spectrometry analysis. Peptides were
dissolved in sterile phosphate-buffered saline (PBS),
diluted to 2 mg/ml and frozen at -80 °C until required.
Construction of the vaccines
Briefly, Ad5-GPS and Ad5-GPZ were generated using
the appropriate open reading frames for the genes en-
coding the glycoprotein of SEBOV (Genbank accession
number EVU28134) or ZEBOV (Genbank accession
number NC-002549), respectively. These were cloned
into the adenoviral shuttle plasmid pDC316. The shuttle
plasmid and the adenoviral backbone plasmid
(pBHGlox_E1, 3Cre) were co-transfected into HEK293
cells using Lipofectamine™ Reagent (Invitrogen, Carls-
bad, California, USA), following the manufacturer’s
instructions. Transfected cells were maintained until
adenovirus-related cytopathic effects were observed. The
adenoviruses were harvested and confirmed by polymer-
ase chain reaction (PCR). Positive recombinant adeno-
viruses were reamplified in HEK293 cells and purified by
ion exchange (SOURCE 15Q) and size exclusion. The
viruses were titrated on HEK293 cells using an Adeno-
X™ Rapid Titer Kit (Clontech, Japan). The resulting titers
were scored as infectious units (IFU)/ml.
Animal experiments and splenocytes dissociation
Female BALB/c (H-2d) mice that were 4–6-weeks-old
were purchased from the Laboratory Animal Centre in
National Institute for the Control of Pharmaceutical and
Biological Products (P.R. China). Mice were immunized
with 1 × 107 IFU of adenovirus (Ad5-GPS, Ad5-GPZ, or
the control adenovirus vector Ad5-EGFP) via an intra-
muscular route twice, at an interval of 4 weeks. All mice
were handled according to protocols approved by the
Laboratory Animal Care and Use Committee, of the Bei-
jing Institute of Microbiology and Epidemiology, and
conformed with national guidelines on the ethical use of
laboratory animals. Splenocytes from the immunized
and control mice were harvested 10 days after the sec-
ond immunization. Under aseptic conditions, spleens
were pushed through a 70-μm cell strainer in complete
RPMI1640 medium to prepare a single cell suspension.
Splenocytes were centrifuged at 500 × g for 5 min, the
supernatant was discarded, and red blood cells removed
with ACK lysing buffer (0.15 M of NH4Cl, 10 mM of
KHCO3, 0.1 mM of Na2EDTA, pH 7.2–7.4). Cells were
washed twice in complete RPMI 1640 medium, counted,
and kept on ice until required.
ELISPOT assay
A BD™ ELISPOT Mouse IFN-γ Set was used to count
peptide-specific T cells. ELISPOT plates were coated
overnight at 4 °C with 5 μg/ml of anti-mouse IFN-γantibody. The antibody-coated plates were washed two
times with sterile PBS and blocked with complete RPMI
medium for 2 h at room temperature. After blocking,
100 μl of splenocyte suspension (2 × 106 cells/ml) con-
taining different peptides (20 μg/ml) were added to each
well. A positive control [50 ng/ml phorbol myristate
acetate (PMA; Sigma, Santa clara, California, USA) and
500 ng/ml ionomycin (Sigma)] and a ‘no peptide’ nega-
tive control were included in all assays. The plates were
incubated for 18 h at 37 °C/5% CO2. Following incuba-
tion, the wells were washed twice with deionized water
and three times with washing buffer (PBS containing
0.05% Tween-20). Biotinylated anti-mouse IFN-γ was
added to each well at a concentration of 2 μg/ml and the
plates were incubated for 2 h at room temperature. Fol-
lowing three washes, streptavidin-horseradish peroxidase
was added to each well and the plates were incubated
for 1 h at room temperature. After four washes with
washing buffer and two washes with PBS, the colorimet-
ric reactions were developed using 3-amino 9-
ethylcarbazole as a substrate. Upon visualization of the
spots, the reaction was stopped by rinsing in tap water.
Membranes were allowed to dry overnight in the dark
and then spots were counted with a BioReaderW 4000
Pro-X (Bio-Sys; Germany). Results were expressed as the
number of spot-forming cells (SFCs)/106 splenocytes.
Intracellular IFN-γ staining
Splenocytes were cultured at 37 °C for 6 h with 20 μg/
ml synthetic peptide, or with no peptide as the back-
ground control, or with 100 ng/ml PMA and 1 μg/ml
ionomycin as the positive control. For the last 4 h of cul-
ture, 10 μg/ml brefeldin A (BFA, Sigma;) was added to
block the secretion of IFN-γ. Cells were stained with
PerCP/Cy5.5-conjugated anti-CD3 (clone 145-2c11; Bio-
legend, San Diego, California, USA) and FITC conju-
gated anti-CD8 (clone 53-6.7; Biolegend) monoclonal
antibodies, then fixed and permeabilized with Cytofix/
Cytoperm (BD Biosciences, Franklin Lake, New Jersey,
USA). The permeabilized cells were incubated with PE-
conjugated anti-IFN-γ (clone XMG1.2; BD Bioscience),
washed and resuspended in PBS. Samples were analyzed
using a Beckman Coulter CyAn™ ADP flow cytometer
and Summit software.
Statistical analysis
Data were expressed as means ± standard errors of the
means (SEM). Statistical analysis was performed with
two-tailed unpaired t tests using Prism 5 (GraphPad
Software). P values of less than or equal to 0.05 were
considered statistically significant.
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